Scientific Presentations


Pharmacokinetic and Safety Profile of CTP-692 (Deuterated D-Serine) Following Administration of Single and Multiple Ascending Doses in Healthy Volunteers
32nd The European College of Neuropsychopharmacology Congress
September 10, 2019

CTP-543 Phase 2 Results in Patients with Moderate-to-Severe Alopecia Areata
September 3, 2019

Phase 1 Healthy Volunteer Pharmacokinetic and Safety Profile of D-Serine Compared to CTP-692, a Novel Deuterium-Modified D-Serine for Adjunctive Treatment of Schizophrenia
American Society of Clinical Psychopharmacology
May 28-31, 2019

CTP-543, A JAK1/JAK2 Inhibitor, Achieves Primary Endpoint in Interim Analysis of Phase 2 Trial in Alopecia Areata
2019 World Congress for Hair Research Annual Meeting
April 24-27,2019

JAK Inhibitor CTP-543 Achieves Primary Endpoint in Phase 2 Trial in Alopecia Areata; An Interim Analysis of 4 and 8 mg BID
American Academy of Dermatology
Late-breaking Research: Clinical Trials
March 2, 2019


CTP-692: Selective deuterium modification of D-serine markedly decreases renal toxicity in preclinical testing
American College of Toxicology 2018 Annual Meeting
November 4-7, 2018


Safety and Pharmacokinetic Evaluation of CTP-543 (Deuterated Ruxolitinib) in a Phase 1 Healthy Volunteer Study
2017 American Academy of Dermatology Annual Meeting
March 3-7, 2017


CTP-656 Multiple Dose Pharmacokinetic Profile Continues to Support a Once-Daily Potentiator for Cystic Fibrosis Patients with Gating Mutations
30th Annual North American Cystic Fibrosis Conference
October 27-29, 2016

CTP-656 Tablet Confirmed Superiority of Pharmacokinetic Profile Relative to Kalydeco in Phase 1 Clinical Studies
39th European Cystic Fibrosis Conference
June 8-11, 2016


Pharmacokinetic Studies of Deuterated Isotopologs of Ivacaftor in Preclinical Models and Healthy Volunteers
29th Annual North American Cystic Fibrosis Conference
October 8-10, 2015

Back to Top